Recently, Sotagliflozin, a dual SGLT1/2 inhibitor, has gained FDA approval for reducing the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visits in patients with heart failure or type 2 diabetes, CKD, and other cardiovascular risk factors (Packer, 2023). This evidence concerns the gene SLC5A1 and heart failure.